cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.7nns2t
title: Occurrence Download

description: A dataset containing 3836 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is one of (Fossil, Living Specimen)"
 ]
 }
 },
 "TaxonKey is Palaquium Blanco"
 ]
}

 The dataset includes 3836 records from 69 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0009832-250515123054153/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.m3ajdu
title: Occurrence Download

description: A dataset containing 109 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 "BasisOfRecord is one of (Human Observation, Machine Observation, Occurrence evidence, Observation)",
 "TaxonKey is one of (Manis javanica Desmarest, 1822)",
 "Country is one of (Afghanistan, Armenia, Azerbaijan, Bahrain, Bangladesh, Bhutan, Brunei Darussalam, Cambodia, China, Cyprus, Georgia, Hong Kong, India, Indonesia, Iran (Islamic Republic of), Iraq, Israel, Japan, Jordan, Kazakhstan, Korea (Democratic People’s Republic of), Korea, Republic of, Kuwait, Kyrgyzstan, Lao People’s Democratic Republic, Lebanon, Macao, Malaysia, Maldives, Mongolia, Myanmar, Nepal, Oman, Pakistan, Palestine, State of, Philippines, Qatar, Saudi Arabia, Singapore, Sri Lanka, Syrian Arab Republic, Tajikistan, Thailand, Timor-Leste, Türkiye, Turkmenistan, United Arab Emirates, Uzbekistan, Viet Nam, Yemen)"
 ]
}

 The dataset includes 109 records from 7 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0016176-250525065834625/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.rtm3q5
title: Occurrence Download

description: A dataset containing 1563 species occurrences available in GBIF matching the query:
{
 "and" : [
 "GadmGid is BRA.14.22_2",
 "TaxonKey is Aves"
 ]
}

 The dataset includes 1563 records from 3 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0009667-250515123054153/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.6dfjja
title: Occurrence Download

description: A dataset containing 11 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Meetnetten.be - Area count for Eresus sandaliatus in Flanders, Belgium"
 ]
}

 The dataset includes 11 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0033626-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.57745/foukhp
title: DRYvER_WP2_Macroinvertebrate_CELAC_Data Dictionary.tab

description: :unav
DOI: 10.57745/tjwjzw
title: DRYvER_WP2_Fish_EU.tab

description: :unav
DOI: 10.57745/zxcjcr
title: DRYvER_WP2_Macroinvertebrate_CELAC_DB Schema.jpg

description: :unav
DOI: 10.57745/qagby3
title: DRYvER_WP2_Fish_EU_DB Schema.png

description: :unav
DOI: 10.57745/8omk66
title: DRYvER_WP2_Fish_EU_Data Dictionary.tab

description: :unav
DOI: 10.57745/iwhblj
title: DRYvER_WP2_Fish_EU_data.tab

description: :unav
DOI: 10.15468/dl.ua9xv5
title: Occurrence Download

description: A dataset containing 1192 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Meetnetten.be - Chorus counts for Amphibia in Flanders, Belgium"
 ]
}

 The dataset includes 1192 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0033627-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.30621308
title: Dry weight of western honey bees emerged from larvae fed different diets.

description: Key to variable names & types:<br>colony -- colony ID (categorical)plate -- test plate ID (categorical)number -- larva ID (categorical)treatment -- diet type (categorical)fresh -- fresh weight (g) (numerical)
DOI: 10.6084/m9.figshare.30621308.v1
title: Dry weight of western honey bees emerged from larvae fed different diets.

description: Key to variable names & types:<br>colony -- colony ID (categorical)plate -- test plate ID (categorical)number -- larva ID (categorical)treatment -- diet type (categorical)fresh -- fresh weight (g) (numerical)
DOI: 10.5281/zenodo.17611492
title: Dataset: A signal convention in natural chimpanzee communication

description: Dataset, code, and video for the article
DOI: 10.5281/zenodo.17554044
title: Levin et al. - Deployment Pathways for Long Duration Energy Storage - A-LEAF Model Data
DOI: 10.5281/zenodo.17554043
title: Levin et al. - Deployment Pathways for Long Duration Energy Storage - A-LEAF Model Data
DOI: 10.15468/dl.fkj7cz
title: Occurrence Download

description: A dataset containing 21299 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Meetnetten.be - Egg counts for butterflies in Flanders, Belgium"
 ]
}

 The dataset includes 21299 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0033633-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.28652343.v1
title: Advanced Parkinson’s disease and eligibility for device-aided therapies in Morocco: a multicenter cross-sectional study

description: This study investigates the prevalence and clinical features of advanced Parkinson’s disease (APD) in Moroccan patients and evaluates their eligibility for Device-Aided Therapies (DATs), including Deep Brain Stimulation (DBS), Continuous Subcutaneous Apomorphine Infusion (CSAI), and Levodopa-Carbidopa Intestinal Gel infusion (LCIG). We conducted a cross-sectional study across 15 facilities in five cities within the Casablanca-Settat region, Morocco. We collected demographics, clinical, and health-related quality of life data. Logistic regression identified factors predicting disease progression and DATs eligibility. This study included 370 patients with Parkinson’s disease, of whom 44.6% (95%CI: 39.5%-49.8%) had APD. Each additional year of disease duration increased APD odds by 8% (ORa = 1.08, <i>p</i> = 0.047). Overall, 38.9% of patients qualified for at least one DAT, including 18.9% for DBS, 35.4% for CSAI, and 13.8% for LCIG; however, only one patient received DBS. Younger age at onset was associated with greater DATs eligibility, with each additional year reducing eligibility by 7% (ORa = 0.93, <i>p</i> &lt; 0.001). Additionally, premotor REM sleep behavior disorder increased the odds of LCIG eligibility (ORa = 2.38, <i>p</i> = 0.009), while prior sports engagement nearly tripled the odds for CSAI (ORa = 2.87, <i>p</i> = 0.038). Although many Moroccan patients qualify for DATs, their use is minimal. Addressing access barriers is crucial to improve outcomes.
DOI: 10.6084/m9.figshare.28652343
title: Advanced Parkinson’s disease and eligibility for device-aided therapies in Morocco: a multicenter cross-sectional study

description: This study investigates the prevalence and clinical features of advanced Parkinson’s disease (APD) in Moroccan patients and evaluates their eligibility for Device-Aided Therapies (DATs), including Deep Brain Stimulation (DBS), Continuous Subcutaneous Apomorphine Infusion (CSAI), and Levodopa-Carbidopa Intestinal Gel infusion (LCIG). We conducted a cross-sectional study across 15 facilities in five cities within the Casablanca-Settat region, Morocco. We collected demographics, clinical, and health-related quality of life data. Logistic regression identified factors predicting disease progression and DATs eligibility. This study included 370 patients with Parkinson’s disease, of whom 44.6% (95%CI: 39.5%-49.8%) had APD. Each additional year of disease duration increased APD odds by 8% (ORa = 1.08, <i>p</i> = 0.047). Overall, 38.9% of patients qualified for at least one DAT, including 18.9% for DBS, 35.4% for CSAI, and 13.8% for LCIG; however, only one patient received DBS. Younger age at onset was associated with greater DATs eligibility, with each additional year reducing eligibility by 7% (ORa = 0.93, <i>p</i> &lt; 0.001). Additionally, premotor REM sleep behavior disorder increased the odds of LCIG eligibility (ORa = 2.38, <i>p</i> = 0.009), while prior sports engagement nearly tripled the odds for CSAI (ORa = 2.87, <i>p</i> = 0.038). Although many Moroccan patients qualify for DATs, their use is minimal. Addressing access barriers is crucial to improve outcomes.
DOI: 10.6084/m9.figshare.28731496
title: Real-world evidence of riluzole on survival and ALSFRS change in a Chinese ALS cohort

description: This study aimed to evaluate the effects of riluzole on survival and changes in ALS Functional Rating Scale (ALSFRS) among Chinese patients with Amyotrophic Lateral Sclerosis (ALS). Propensity score matching was used to balance baseline variables between the riluzole group (<i>n</i> = 238) and control group (<i>n</i> = 454). Survival was analyzed using Kaplan – Meier curves and Cox regression, while multivariable linear regression assessed ALSFRS changes at 6 and 12 months. Subgroup analyses were conducted to identify potential responders. Riluzole did not significantly improve survival (<i>p</i> = 0.478) or ALSFRS changes at 6 months (<i>p</i> = 0.380) or 12 months (<i>p</i> = 0.175). Subgroup analyses revealed no survival benefit in any subgroup, and further stratification showed inconsistent adverse effects on ALSFRS scores. Riluzole neither prolonged survival nor slowed functional decline in Chinese ALS patients, with no subgroup demonstrating a better response.
DOI: 10.6084/m9.figshare.28731496.v1
title: Real-world evidence of riluzole on survival and ALSFRS change in a Chinese ALS cohort

description: This study aimed to evaluate the effects of riluzole on survival and changes in ALS Functional Rating Scale (ALSFRS) among Chinese patients with Amyotrophic Lateral Sclerosis (ALS). Propensity score matching was used to balance baseline variables between the riluzole group (<i>n</i> = 238) and control group (<i>n</i> = 454). Survival was analyzed using Kaplan – Meier curves and Cox regression, while multivariable linear regression assessed ALSFRS changes at 6 and 12 months. Subgroup analyses were conducted to identify potential responders. Riluzole did not significantly improve survival (<i>p</i> = 0.478) or ALSFRS changes at 6 months (<i>p</i> = 0.380) or 12 months (<i>p</i> = 0.175). Subgroup analyses revealed no survival benefit in any subgroup, and further stratification showed inconsistent adverse effects on ALSFRS scores. Riluzole neither prolonged survival nor slowed functional decline in Chinese ALS patients, with no subgroup demonstrating a better response.
DOI: 10.6084/m9.figshare.29039253
title: BMI and sex disparity in uric acid level improvement in patients with obesity and diabetes following laparoscopic sleeve gastrectomy

description: The potential improvement in uric acid (UA) levels following laparoscopic sleeve gastrectomy (LSG) in patients with obesity and type II diabetes mellitus (T2DM) has not been systematically studied. Our aim was to investigate the influencing factors of UA level improvement following LSG and its correlation with glucose metabolism and lipid metabolism. A total of 392 patients with obesity and T2DM were prospectively recruited from 1 November 2022 to 31 December 2023. All patients underwent LSG surgery and were followed at 1, 2, 3, 6, 12 months after surgery. The presurgical and postsurgical levels of body-mass index(BMI), UA and indicators of glucose metabolism and lipid metabolism were recorded. Distinct UA improvement was observed between males and females and among different BMI groups following LSG. Female patients exhibited more sustained and greater recovery of UA level up to 12 months than male patients in all BMI groups, although male patients showed a sharper UA level decrease in the first two months. Furthermore, patients with BMI ≥ 37.5 appeared to have significantly greater UA level decrease than other patients up to 12 months. UA level improvement showed significant correlation with BMI improvement in all three BMI groups in females while only in BMI 28–32.5 group in males. For glucose metabolism, a significant linear correlation between UA level changes and fasting blood glucose (FBG), fasting blood insulin (FBI), glycosylated hemoglobin A1c (HbA1c) and C-peptide (CP) was found in patients with presurgical elevated UA level group, and in female patients for FBI and CP. For lipid metabolism, a significant linear correlation was only observed between UA level changes and HDL in female and those with high presurgical UA levels. Sex and presurgical BMI appeared to influence the UA improvement following LSG. Females and those with presurgical elevated UA levels exhibited the most significant UA level alleviation. UA level changes also correlated with glucose metabolism and lipid metabolism.
DOI: 10.6084/m9.figshare.29039253.v1
title: BMI and sex disparity in uric acid level improvement in patients with obesity and diabetes following laparoscopic sleeve gastrectomy

description: The potential improvement in uric acid (UA) levels following laparoscopic sleeve gastrectomy (LSG) in patients with obesity and type II diabetes mellitus (T2DM) has not been systematically studied. Our aim was to investigate the influencing factors of UA level improvement following LSG and its correlation with glucose metabolism and lipid metabolism. A total of 392 patients with obesity and T2DM were prospectively recruited from 1 November 2022 to 31 December 2023. All patients underwent LSG surgery and were followed at 1, 2, 3, 6, 12 months after surgery. The presurgical and postsurgical levels of body-mass index(BMI), UA and indicators of glucose metabolism and lipid metabolism were recorded. Distinct UA improvement was observed between males and females and among different BMI groups following LSG. Female patients exhibited more sustained and greater recovery of UA level up to 12 months than male patients in all BMI groups, although male patients showed a sharper UA level decrease in the first two months. Furthermore, patients with BMI ≥ 37.5 appeared to have significantly greater UA level decrease than other patients up to 12 months. UA level improvement showed significant correlation with BMI improvement in all three BMI groups in females while only in BMI 28–32.5 group in males. For glucose metabolism, a significant linear correlation between UA level changes and fasting blood glucose (FBG), fasting blood insulin (FBI), glycosylated hemoglobin A1c (HbA1c) and C-peptide (CP) was found in patients with presurgical elevated UA level group, and in female patients for FBI and CP. For lipid metabolism, a significant linear correlation was only observed between UA level changes and HDL in female and those with high presurgical UA levels. Sex and presurgical BMI appeared to influence the UA improvement following LSG. Females and those with presurgical elevated UA levels exhibited the most significant UA level alleviation. UA level changes also correlated with glucose metabolism and lipid metabolism.
DOI: 10.5281/zenodo.17187910
title: Data from: One Giant Leap for Womankind: First Menstrual Cups Tested in Spaceflight Conditions

description: Metadata of payload on board the Baltasar rocket during EuRoC competition in 2022. The data includes Time (s),  Temperature (ºC), Pressure (Pa),    Acceleration (G), and   Humidity (%).
description: Funder acknowledgements

L.F.C. is funded by the Heising-Simons Foundation 51 Pegasi b postdoctoral fellowship 2024-5174. The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the manuscript. The authors gratefully acknowledge the Rocket Experiment Division (RED) and the Aerospace Engineering Students' Organization (AeroTéc) from Instituto Superior Técnico, for all work and data related to the Baltasar rocket. We extend our sincere appreciation to the RED team for selecting our proposal, which made the menstrual cup flight experiment possible. Catarina Pereira is gratefully acknowledged for her significant contributions to the study's conceptualization, logistics and experimental work. The authors acknowledge the European Rocket Challenge (EuRoC). The authors acknowledge Lunette for donating the menstrual cups for the study.
DOI: 10.6084/m9.figshare.28935802
title: Daily solriamfetol improved performance on a memory and attention task in people with obstructive sleep apnea and excessive daytime sleepiness: a plain language summary

description: <b>What is this summary about?</b> The SHARP study looked at the effects of a medication called solriamfetol in people with obstructive sleep apnea (sleep apnea for short) who were very sleepy during the day (called excessive daytime sleepiness) and had trouble with things like thinking, concentrating, and remembering (called cognitive impairment). In people with sleep apnea, breathing is regularly interrupted during sleep. This can lead to many problems, including excessive daytime sleepiness and <b>cognitive</b> impairment. In previous studies, people with sleep apnea and excessive daytime sleepiness who took solriamfetol felt more awake during the day compared with people who took an identical tablet with no medication (called a <b>placebo</b>). The SHARP study looked at the effects of solriamfetol on symptoms related to cognitive impairment. To avoid <b>bias</b> from people’s personal feelings about their cognition, the cognitive function of people who participated in the study was measured by a cognitive performance test (called objective cognitive function). Subjective ratings were also used; these measured people’s personal feelings about their cognitive function (called subjective cognitive function), the severity of their cognitive impairment, and their sleepiness during the day. <b>What are the key takeaways?</b> In the SHARP study, people had more improvement in their objective cognitive function when taking solriamfetol than when they took placebo, and this benefit lasted for 8 hours. People also reported that their subjective cognitive function had improved, their cognitive impairment was less severe, and their daytime sleepiness was better with solriamfetol. The most common side effects were nausea and anxiety. <b>What were the main conclusions reported by the researchers?</b> These findings show that solriamfetol can improve cognitive function in people with cognitive impairment related to sleep apnea and excessive daytime sleepiness.
DOI: 10.6084/m9.figshare.28935802.v1
title: Daily solriamfetol improved performance on a memory and attention task in people with obstructive sleep apnea and excessive daytime sleepiness: a plain language summary

description: <b>What is this summary about?</b> The SHARP study looked at the effects of a medication called solriamfetol in people with obstructive sleep apnea (sleep apnea for short) who were very sleepy during the day (called excessive daytime sleepiness) and had trouble with things like thinking, concentrating, and remembering (called cognitive impairment). In people with sleep apnea, breathing is regularly interrupted during sleep. This can lead to many problems, including excessive daytime sleepiness and <b>cognitive</b> impairment. In previous studies, people with sleep apnea and excessive daytime sleepiness who took solriamfetol felt more awake during the day compared with people who took an identical tablet with no medication (called a <b>placebo</b>). The SHARP study looked at the effects of solriamfetol on symptoms related to cognitive impairment. To avoid <b>bias</b> from people’s personal feelings about their cognition, the cognitive function of people who participated in the study was measured by a cognitive performance test (called objective cognitive function). Subjective ratings were also used; these measured people’s personal feelings about their cognitive function (called subjective cognitive function), the severity of their cognitive impairment, and their sleepiness during the day. <b>What are the key takeaways?</b> In the SHARP study, people had more improvement in their objective cognitive function when taking solriamfetol than when they took placebo, and this benefit lasted for 8 hours. People also reported that their subjective cognitive function had improved, their cognitive impairment was less severe, and their daytime sleepiness was better with solriamfetol. The most common side effects were nausea and anxiety. <b>What were the main conclusions reported by the researchers?</b> These findings show that solriamfetol can improve cognitive function in people with cognitive impairment related to sleep apnea and excessive daytime sleepiness.
DOI: 10.5281/zenodo.17187909
title: Data from: One Giant Leap for Womankind: First Menstrual Cups Tested in Spaceflight Conditions

description: Metadata of payload on board the Baltasar rocket during EuRoC competition in 2022. The data includes Time (s),  Temperature (ºC), Pressure (Pa),    Acceleration (G), and   Humidity (%).
description: Funder acknowledgements

L.F.C. is funded by the Heising-Simons Foundation 51 Pegasi b postdoctoral fellowship 2024-5174. The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the manuscript. The authors gratefully acknowledge the Rocket Experiment Division (RED) and the Aerospace Engineering Students' Organization (AeroTéc) from Instituto Superior Técnico, for all work and data related to the Baltasar rocket. We extend our sincere appreciation to the RED team for selecting our proposal, which made the menstrual cup flight experiment possible. Catarina Pereira is gratefully acknowledged for her significant contributions to the study's conceptualization, logistics and experimental work. The authors acknowledge the European Rocket Challenge (EuRoC). The authors acknowledge Lunette for donating the menstrual cups for the study.
DOI: 10.6084/m9.figshare.30621374
title: Change-Point Detection in Time Series Using Mixed Integer Programming*

description: We use cutting-edge mixed integer optimization (MIO) methods to develop a framework for detection and estimation of structural breaks in time series regression models. The framework is constructed based on the least squares problem subject to a penalty on the number of breakpoints. We restate the l0-penalized regression problem as a quadratic programming problem with integer- and real-valued arguments and show that MIO is capable of finding provably optimal solutions using a well-known optimization solver. Compared to the popular l1-penalized regression (LASSO) and other classical methods, the MIO framework permits simultaneous estimation of the number and location of structural breaks as well as regression coefficients, while accommodating the option of specifying a given or minimal number of breaks. We derive the asymptotic properties of the estimator and demonstrate its effectiveness through extensive numerical experiments, confirming a more accurate estimation of multiple breaks as compared to popular non-MIO alternatives. Two empirical examples demonstrate usefulness of the framework in applications from business and economic statistics.